Yan V. Wang

1.4k total citations · 1 hit paper
8 papers, 878 citations indexed

About

Yan V. Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Yan V. Wang has authored 8 papers receiving a total of 878 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Surgery. Recurrent topics in Yan V. Wang's work include Renal cell carcinoma treatment (3 papers), Ovarian cancer diagnosis and treatment (3 papers) and Phagocytosis and Immune Regulation (2 papers). Yan V. Wang is often cited by papers focused on Renal cell carcinoma treatment (3 papers), Ovarian cancer diagnosis and treatment (3 papers) and Phagocytosis and Immune Regulation (2 papers). Yan V. Wang collaborates with scholars based in United States, Germany and France. Yan V. Wang's co-authors include Amreen Husain, Barbara A. Goff, Lawrence R. Nycum, Carol Aghajanian, Stephanie V. Blank, Omid Hamid, Priti S. Hegde, John D. Powderly, Marcella Fassò and Jeffrey A. Sosman and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Allergy and Clinical Immunology and Gynecologic Oncology.

In The Last Decade

Yan V. Wang

8 papers receiving 862 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

2016 409 citations David F. McDermott, Jeffrey A. Sosman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yan V. Wang United States	7	527	276	258	201	165	8	878
Min Sung An South Korea	12	155 0.3×	133 0.5×	176 0.7×	217 1.1×	145 0.9×	42	705
Michael A. Ströhlein Germany	16	497 0.9×	169 0.6×	212 0.8×	220 1.1×	570 3.5×	24	1.1k
Katarína Macháleková Slovakia	15	264 0.5×	174 0.6×	88 0.3×	96 0.5×	283 1.7×	47	684
Peter Lim Canada	16	316 0.6×	145 0.5×	95 0.4×	806 4.0×	117 0.7×	32	1.5k
W. Schröder Germany	18	274 0.5×	163 0.6×	201 0.8×	576 2.9×	356 2.2×	57	1.3k
Anna Pesci Italy	17	302 0.6×	244 0.9×	49 0.2×	320 1.6×	362 2.2×	42	1.3k
AA Bartolucci United States	12	242 0.5×	166 0.6×	188 0.7×	57 0.3×	222 1.3×	20	861
Taymaa May Canada	17	259 0.5×	96 0.3×	80 0.3×	662 3.3×	317 1.9×	94	1.1k
Laura Ardighieri Italy	16	181 0.3×	80 0.3×	106 0.4×	200 1.0×	137 0.8×	43	616
Emanuela Veras United States	14	228 0.4×	173 0.6×	145 0.6×	552 2.7×	153 0.9×	25	1.2k

Countries citing papers authored by Yan V. Wang

Since Specialization

Citations

This map shows the geographic impact of Yan V. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan V. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan V. Wang more than expected).

Fields of papers citing papers by Yan V. Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan V. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan V. Wang. The network helps show where Yan V. Wang may publish in the future.

Co-authorship network of co-authors of Yan V. Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Yan V. Wang. A scholar is included among the top collaborators of Yan V. Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan V. Wang. Yan V. Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Fisher, George A., Nehal J. Lakhani, Cathy Eng, et al.. (2020). A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.. Journal of Clinical Oncology. 38(4_suppl). 114–114. 41 indexed citations

2.

Lakhani, Nehal J., Amita Patnaik, John B. Liao, et al.. (2020). A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.. Journal of Clinical Oncology. 38(5_suppl). 18–18. 30 indexed citations

3.

McDermott, David F., Jeffrey A. Sosman, Mario Sznol, et al.. (2016). Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. Journal of Clinical Oncology. 34(8). 833–842. 409 indexed citations breakdown →

4.

Aghajanian, Carol, Barbara A. Goff, Lawrence R. Nycum, et al.. (2015). Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology. 139(1). 10–16. 222 indexed citations

5.

Namazy, Jennifer A., Michael D. Cabana, Angela E. Scheuerle, et al.. (2014). The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy. Journal of Allergy and Clinical Immunology. 135(2). 407–412. 149 indexed citations

6.

Aghajanian, Carol, Barbara A. Goff, Lawrence R. Nycum, et al.. (2014). Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. Gynecologic Oncology. 133(1). 105–110. 18 indexed citations

7.

Husain, Amreen, Yan V. Wang, Rikke Frederiksen, et al.. (2014). Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab (BV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).. Journal of Clinical Oncology. 32(15_suppl). 5540–5540. 2 indexed citations

8.

Miles, David, Leonardo Faoro, Yan V. Wang, & Joyce O’Shaughnessy. (2013). MERiDiAN: A phase III, randomized, double-blind study of the efficacy, safety, and associated biomarkers of bevacizumab plus paclitaxel compared with paclitaxel plus placebo, as first-line treatment of patients with HER2-negative metastatic breast cancer.. Journal of Clinical Oncology. 31(15_suppl). TPS1142–TPS1142. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact